Introduction
============

Jass ([@B9]) proposed a molecular classification of colorectal cancer based predominantly on five features: CpG island methylator phenotype (CIMP), microsatellite instability (MSI), *KRAS*, *BRAF*, and methylation status of 0-6-Methylguanine DNA Methyltransferase (*MGMT*). The new classification was composed of five molecular subtypes, with the largest group including mostly CIMP-negative, chromosomally instable (CIN), microsatellite stable (MSS) colorectal cancers (57% of cases). In addition, CIMP-low (CIMP-L), *KRAS* mutated, *MGMT* methylated, MSS/MSI-low (MSI-L) cancers were predicted in 20% of cases, while CIMP-H, *BRAF* mutated, MSI-H tumors in 12%, CIMP-H, *BRAF* mutated, chromosomally stable, MSS/MSI-L in 8%, and finally, the hereditary Lynch syndrome CIMP-negative, *BRAF* mutation-negative, chromosomally stable, and MSI-H cancers found in 3% of all cases. Indeed, these new subgroupings form the basis of the current model of colorectal tumorigenesis.

To date, the prognostic relevance of Jass's proposed groupings, particularly those arising in the sporadic context, has not yet been tested. As single molecular entities, *KRAS* mutations and MSI have been intensively investigated, while mutations in *BRAF* and analysis of CIMP are fewer (Andreyev et al., [@B2]; Boland and Goel, [@B3]). Less than a handful of studies have evaluated the prognostic relevance of *MGMT* (Shima et al., [@B22]). CIMP-H and MSI-H colorectal cancers seem to share similar features including proximal tumor location, mucinous histological type, poorer tumor grade, and *BRAF* mutation, but they may be inter-dependent in terms of their prognostic effects (Ogino et al., [@B18]; Sanchez et al., [@B21]; Dahlin et al., [@B6]). Patients with MSI-H cancers may benefit from a decreased rate of distant metastasis and longer survival time when compared to their MSS counterparts (Kloor et al., [@B13]) whereas patients with CIMP-H cancers particularly in the MSS context seem to have a considerably more unfavorable outcome (Ward et al., [@B27]; Dahlin et al., [@B6]; Kloor et al., [@B13]). Also, *BRAF* mutated cancers may lead to poorer survival time in MSS cancers only (Samowitz et al., [@B20]).

The aim of this study was first to classify a cohort of 302 colorectal cancers according to the proposed molecular classification based on CIMP, *MGMT* methylation, *KRAS* and *BRAF* mutation, and MSI and then, to test its prognostic value.

Materials and Methods
=====================

Patients
--------

About 1420 primary pre-operatively untreated, unselected sporadic colorectal cancer patients treated between the years 1987 and 1996 were initially included in this study. Hematoxylin and eosin (H&E) stained slides were retrospectively collected from the Institute of Pathology, University Hospital of Basel, the Institute of Clinical Pathology, Basel, Switzerland, and the Institute of Pathology, Stadtspital Triemli, Zürich, Switzerland. From this larger subgroup, only 600 paraffin-embedded tissue blocks could be retrieved. Histopathological criteria were reviewed by an experienced gastrointestinal pathologist. The tumor border configuration (pushing/expanding or infiltrating) as well as the presence of peritumoral lymphocytic inflammation at the invasive tumor front were scored according to Jass ([@B8]). Clinical data including patient age at diagnosis, tumor location, and follow-up were retrieved from patient records. Clinical outcome of interest was cancer-specific survival time. Censored observations included patients who were alive at the last follow-up, died for reasons other than colorectal cancer or were lost to follow-up. Patient characteristics are summarized in Table [1](#T1){ref-type="table"}. The use of material for this study was approved by the ethics committee of the University Hospital of Basel.

###### 

**Patient characteristics (*n* = 337)**.

                                                     Freq (%)               
  -------------------------------------------------- ---------------------- ---------------
  Age (years; *n* = 313)                             Mean, range            69.9 (42--95)
  Tumor diameter (mm; *n* = 307)                     Mean, range            51.3 (5--160)
  Gender (*n* = 337)                                 Female                 181 (53.7)
                                                     Male                   156 (46.3)
  Tumor location (*n* = 335)                         Left-sided             210 (62.7)
                                                     Right-sided            125 (37.3)
  Histological subtype (*n* = 337)                   Non-mucinous           314 (93.2)
                                                     Mucinous               23 (6.8)
  pT classification (*n* = 331)                      pT1--2                 72 (21.8)
                                                     pT3--4                 259 (78.2)
  pN classification (*n* = 326)                      pN0                    177 (54.3)
                                                     pN1--2                 149 (45.7)
  Tumor grade (*n* = 331)                            G1-2                   310 (93.7)
                                                     G3                     21 (6.3)
  Vascular invasion (*n* = 331)                      Absent                 233 (70.4)
                                                     Present                98 (29.6)
  Tumor border (*n* = 329)                           Pushing                98 (29.8)
                                                     Infiltrating           231 (70.2)
  Peritumoral lymphocytic inflammation (*n* = 331)   Absent                 255 (77.0)
                                                     Present                76 (23.0)
  *KRAS* (codon 12 and 13; *n* = 325)                Wild-type              226 (69.5)
                                                     Mutation               99 (30.5)
  *BRAF* (codon V600E; *n* = 314)                    Wild-type              272 (86.6)
                                                     Mutation               42 (13.4)
  MSI status (*n* = 337)                             Stable/instable--low   281 (83.4)
                                                     Instable--high         56 (16.6)
  CIMP (*n* = 337)                                   Negative               168 (49.9)
                                                     Low                    145 (43.0)
                                                     High                   24 (7.1)
  *MGMT* (*n* = 337)                                 Non-methylated         225 (66.8)
                                                     Methylated             112 (33.2)

Assay Methods
-------------

### DNA isolation, mutation, and microsatellite instability analysis

In order to identify regions for punching and DNA extraction, neoplastic, and adjacent non-neoplastic tissue areas were marked on the H&E slide by an experienced pathologist (A.L) with pens of two different colors. Only blocks with \>70% tumor content were used for this purpose.

Genomic DNA was obtained from both primary tumors and adjacent non-neoplastic tissues using NucleoMag 96 Tissue Kit (Macherey Nagel) protocol and processed in the Xiril X-100 robot (Xiril, Hombrechtikon, Switzerland). Briefly, punched tissue was lysed in proteinase K. B-beads and MB2 buffer were added to the cleared lysate, shaken for 5 min at RT. The supernatant was removed and MB3 buffer was added followed by shaking and supernatant removal. The genomic DNA was eluted with MB6 buffer. Genomic DNA was amplified by PCR using AmpliTaq Gold polymerase (Applied Biosystems). *KRAS* (exon 2 codon 12 and 13) and *BRAF* (exon 15 codon 600) were amplified by a first and a nested PCR. Residual primers were removed using the EXOSAPit (Amersham). Samples were then subjected to direct sequencing of single-stranded PCR products using the BigDye^®^ Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and the ABI Prism^®^ 3130 genetic analyzer (Applied Biosystems). All products were sequenced bi-directionally. Analysis of MSI status was based on the multiplex amplification of the five microsatellites (BAT25, BAT26, D2S123, D5S346, D17S250). An initial denaturation step at 95°C for 10 min was followed by 42 cycles at 95°C for 40 s, 54°C for 40 s, and 72°C for 60 s. For the analysis, 1 μl of the DNA weight marker ROX 500 (Applied Biosystem) was added and 10 μl of deionized formamide in 3 μl of the PCR amplified solution. DNA was denaturated by incubation for 2 min at 95°C. The POP-7 polymer solution (Applied Biosystem) was used for the electrophoresis on the ABI Prism^®^ 3130 genetic analyzer (Applied Biosystems). MSS and MSI-L status were defined as instability at zero and one microsatellite, respectively. MSI-H was characterized by the presence of instability in 40% (≥2 markers; Umar et al., [@B25]).

### DNA bisulfite treatment

DNA denaturation and bisulfite conversion were processed into one-step using the EZ-96 DNA Methylation-GoldTM Kit (Cat. No. D5007, Zymo Research Corporation) according to manufacturer's instructions. Briefly, 130 μl of the CT conversion reagent were added to 20 μl of each DNA sample in a conversion plate. The plates were sealed with the provided film and the conversion plate transferred to a thermal cycler running under the following steps: 98°C for 10 min, 53°C for 4 h, storage at 4°C. Four hundred microliters of M-Binding Buffer were added to the wells of a Silicon-A™ Binding Plate. The samples were transferred from the conversion plate to the wells of the Silicon-A™ binding plate and centrifuged at 3,000 × *g* for 5 min. Each well of the plate was washed using 400 μl of M-wash buffer. The samples were centrifuged at 3,000 × *g* for 5 min. 200 μl of M-Desulphonation buffer was added to each and the plate was placed at room temperature for 20 min followed by centrifugation (3,000 × *g* for 5 min). Two consecutive steps including washing (400 μl of M-wash Buffer) and centrifugation (3,000 × *g* for 5 min) were performed. The Silicon-A™ binding plate was placed onto an elution plate and 30 μl of M-Elution buffer was directly added to each well. 5 min later, the samples were centrifuged at 3,000 × *g* for 3 min to elute the DNA. For control of DNA methylation, Universal Methylated Human DNA Standard was used (Cat. No. D5011, Zymo Research Corporation).

### Amplification of modified DNA

For the first and the nested PCR, 50 cycles of amplification was performed. Two microliters of the modified DNA was added in a volume of 25 μl containing the dNTPs (0.2 mM final), PCR Gold Buffer (1× final, Applied Biosystem), PCR primers (0.12 μM), and 0.2 μl of Taq polymerase (ampliTaq Gold, Applied Biosystem). The nested PCR is performed under the same condition by addition of 1 μl of the amplicon in 25 μl of master mix.

Promoter methylation was assayed for the five CIMP-related genes \[*CRABP1 (HGNC: 2338)*, *MLH1*, *p16INK4a*, *CACNA1G*, *NEUROG1*\] as well as for *MGMT*. For the first and the nested PCR, 50 cycles of amplification were performed. Primer sequences are listed in Table [2](#T2){ref-type="table"}.

###### 

**Primer sequences**.

  ------------------------- ----------------------------- ------------- -------------- ------------------------- -------------------- -------------------------------------- -------------- ------------------------- ---- --------------------
  **MGMT**                  Forward seq                   Tm/position   **Ref NCBI**   **Chromosome/position**   Reverse seq          Tm/position                            **Ref NCBI**   **Chromosome/position**        
  1PCR                      GTTTYGGATATGTTGGGATAGT        52.6          NT 008818.16   10                        2499402--2499423     AATAAAAACRCCTACAAAACCACTC              53.6           NT 008818.16              10   2499558--2499581
  2PCR                      GTTTYGGATATGTTGGGATAGT        52.6          NT 008818.16   10                        2499402--2499423     Biot-AAAACCACTCRAAACTACCACC            54.6           NT 008818.16              10   2499546--2499567
  **Seq primer**            GGATATGTTGGGATAGTT            44.1          NT 008818.16   10                        2499407--2499424                                                                                          
  **CRABP1** A              Forward seq                   Tm                                                                          Reverse seq                            Tm                                            
  1PCR                      AGTTGTTTAAGGTATTGGGTAAG       58.2          NT 010194.17   15                        49423380--49423401   AAACTCCCCAACTTCCACC                    61.4           NT 010194.17              15   49423483--49423500
  2PCR                      AGGTATTGGGTAAGTTGGTGTAG       61.5          NT 010194.17   15                        49423389--49423411   Biot-CAACTTCCACCCCCTCCA                62.1           NT 010194.17              15   49423475--49423492
  **Seq primer**            GGGTAAGTTGGTGTAGA             46.7          NT 010194.17   15                        49423396--49423412                                                                                        
  **MLH1 (lower strand)**   Forward seq                   Tm                                                                          Reverse seq                            Tm                                            
  1PCR                      TGGGGTTTTGTGTTTGGTT           58.2          NT_022517.18   3                         36974265--36974289   AACCTACACRAACAACTCTCTCTTC              57.9           NT_022517.18              3    36974446--36974464
  2PCR                      TGGGGTTTTGTGTTTGGTT           58.2          NT_022517.18   3                         36974313--36974335   Biot-AATCRCCCTAACRCAAACRCTCCACCAAAAC   56.4           NT_022517.18              3    36974446--36974464
  **Seq primer**            GTTATTATGAGGTTGAGT                          NT_022517.18   3                         36974385--36974402                                                                                        
  **CACNA1G**               Forward seq                   Tm                                                                          Reverse seq                            Tm                                            
  1PCR                      GGAAGAGGGGGYGTTTTTTTT         55.9          NT_010783.15   17                        13912553--13912573   TCCCCTACRCCCCTAAAACTT                  55.9           NT_010783.15              17   13912723--13912743
  2PCR                      Biot-GGAAGAGGGGGYGTTTTTTTT    55.9          NT_010783.15   17                        13912553--13912573   CTCCCCCTCACTTTATTC                     54.5           NT_010783.15              17   13912687--13912704
  **Seq primer**            CCCCTCACTTTATTCC              36.7          NT_010783.15   17                        13912686--13912701                                                                                        
  **NEUROG1**               Forward seq                   Tm                                                                          Reverse seq                            Tm                                            
  1PCR                      GTATATTTYGGGTTGGGGGAGG        55.8          NT_34772.6     5                         43185718--43185697   CCCTCCCTTACCACCTC                      59.3           NT_34772.6                5    43185594--43185579
  2PCR                      Biot-GTATATTTYGGGTTGGGGGAGG   55.8          NT_34772.6     5                         43185718--43185697   AATAAATAAAACRAAACRACAAATCATCCCC        53.6           NT_34772.6                5    43185643--43185613
  **Seq primer**            ACAACRCCCRAATATTTACATAATT     45.2          NT_34772.6     5                         43185670--43185645                                                                                        
  **CDKN2A**                Forward seq                   Tm                                                                          Reverse seq                            Tm                                            
  1PCR                      ATGGAGTTTTYGGTTGATTGGT        56.5          NT_008413.18   9                         21964802--21964781   CCCRCCATCCCCTACTCC                     55.2           NT_008413.18              9    21964655--21964638
  2PCR                      ATGGAGTTTTYGGTTGATTGGT        56.5          NT_008413.18   9                         21964802--21964781   Biot-CCCTCTACCCACCTAAAT                56.3           NT_008413.18              9    21964682--21964665
  **Seq primer**            GGAGTTTTAGGTTGATTGGTT         38.1          NT_008413.18   9                         21964800--21964780                                                                                        
  ------------------------- ----------------------------- ------------- -------------- ------------------------- -------------------- -------------------------------------- -------------- ------------------------- ---- --------------------

### Pyrosequencing and CpG site quantification

Three microliters of Sepharose beads were mixed together with 40 μl of binding buffer and 22 μl of water and mixed in an Eppendorf tube. Sixty microliters of this mix was added to 20 μl of PCR products in a 96 well plate and agitated at 1400 rpm for 5 min. The PyroMark Q96 Plate was filled with 0.3 μM of sequencing primer in 40 μl of annealing buffer. The washed were performed using the vacuum station according to the manufacturer instruction. For annealing the samples to sequencing primers, the temperature was increased to 80°C for 2 min and rapidly cooled to room temperature. Plates were then ready for processing in the PyroMarkQ96 instrument.

Pyrosequencing of the purified single-stranded PCR products and CpG site quantification was accomplished by the PyroMarkQ96 and related software (Qiagen). Four to six CpG sites were evaluated for each gene in both neoplastic and corresponding non-neoplastic tissue. Since this method is quantitative, each CpG site is assigned a percentage of methylation. The final CpG score for the tumor or non-neoplastic tissue is represented as the average percentage methylation across all CpG sites for that gene. A tumor-specific methylation score can then be assigned by subtracting out any background methylation from the adjacent non-neoplastic tissue from the tumor's CpG score. This method for calculation is summarized in Figure [1](#F1){ref-type="fig"}. Although the non-neoplastic mucosa is expected to be non-methylated, age-related methylation, and background can still occur (Issa, [@B7]). The threshold tumor-specific methylation score for considering a case as methylation positive was \>30% (minimal difference between tumor and non-neoplastic mucosa). This cut-off score was based on the measured and theoretical percentage of methylation observed at different numbers of PCR amplification cycles using commercially available DNA (unmethylated and 100% methylated, Qiagen) and combinations of the two, resulting in varying degrees of methylation (0, 0.1, 0.3, 1, 3, 10, 30, and 100%). According to these findings, background methylation can be 10% suggesting that a minimal difference in methylation of 20% (10% for tumor and 10% for non-neoplastic) should be used to define methylation-positivity above background. Here, we have used a more stringent criterion of 30% to ensure with even greater certainty a significant degree of methylation. CIMP-H was defined as methylation in ≥4/5 gene loci, while CIMP-L and CIMP-negative were defined as methylation in one to three genes and no gene methylation, respectively.

![**Method of calculation used for determining methylation status**. The pyrograms show percent methylation at five CpG sites in a colorectal cancer and its corresponding normal mucosa; the individual CpG scores are averaged for each. The mean percent methylation from the normal tissue is subtracted from the mean percent methylation of the tumor to give a tumor-specific methylation score. If this final score is ≥30%, then the tumor is considered methylated, otherwise it is considered negative for methylation.](fonc-02-00007-g001){#F1}

Statistical analysis
--------------------

Univariate survival analysis was performed using the Kaplan--Meier method and log-rank test (SAS V9.2; The SAS Institute, Cary, NC, USA). Re-classification of patients into prognostic molecular subgroups was performed using classification and regression tree (CART) analysis with survival status at 10 years follow-up as outcome of interest. To measure the classification error as a function of tree size, 10-fold cross-validation experiments were performed (DTREG Predictive Modeling Software, [www.dtreg.com](www.dtreg.com)).

Results
=======

Frequency of molecular features
-------------------------------

From the 600 cases initially investigated, molecular characterization for CIMP was possible in 337 patients. This was due to the lower quality of DNA which could be extracted from older paraffin-embedded tissues. The frequency of methylation using the proposed criteria were 16% for CDKN2A, 14% for *CACNA1G*, 17% for *MLH1*, 18% for *CRABP1*, 22% for *NEUROG1*. Twenty-four patients (7.1%) were CIMP-H, 145 (43%) CIMP-L, and 168 (49.9%) CIMP-negative. *KRAS* and *BRAF* mutational analysis could be made in 325 and 314 patients, respectively while *MGMT* and MSI analysis was possible in all 337 cases. Thirty-three percent of patients were methylated for *MGMT* and 16.6% had MSI-H tumors. All molecular features could be analyzed in 304 cases. The frequencies of *KRAS* and *BRAF* mutation were 30.5 and 13.3%, respectively while of MSI and *MGMT* methylation was 16.6 and 33.2%.

Classification into proposed subgroups
--------------------------------------

Tumors were then classified into each of Jass Groups 1--5 (Figure [2](#F2){ref-type="fig"}). In Jass Group 1, only six patients (2%) were CIMP-H, *BRAF* mutated and MSI-H, compared to the predicted 12%. In Group 2, there were five patients (2%) with CIMP-H, *BRAF* mutated MSS/MSI-L cancers, compared to the predicted 8%. Next, 13 cases (4%) could be classified into Jass Group 3 containing CIMP-L, MSS/MSI-L, *KRAS* mutated, and *MGMT* methylated tumors, rather than the predicted 20%. Group 4 remained the largest group with 45% of patients (*n* = 137) showing CIMP-negativity, MSS/MSI-L. Finally, Group 5 contained 18 patients (6%) with CIMP-negative, *BRAF* WT, MSI-H cancers. Interestingly, 41% (*n* = 124) of tumors could not be classified into any of the proposed groupings including the remaining 107 (35.4%) CIMP-L cases, 14 CIMP-H, *BRAF* WT (4.6%), and four CIMP-negative, *BRAF* mutated, MSI-H (1.3%).

![**Attempt to classify 302 colorectal cancers into the proposed Jass Groups 1--5**. Forty-one percent of all cases could not be assigned to any one of these subgroups. In parentheses, the asterisk identifies the predicted percentage of patients belonging to each group.](fonc-02-00007-g002){#F2}

Prognostic impact of CIMP and *MGMT*
------------------------------------

The median survival time of the entire cohort was 63 (95%CI: 46--84) months. Patients with CIMP-H colorectal cancers were found to have a significantly lower 10 year survival rate \[22.6% (95%CI): 7--43)\] compared to both CIMP-L \[34.8% (95%CI): 26--43\] and CIMP-negative \[43.4% (95%CI): 34--53\] cancers (*p* = 0.0248; Figure [3](#F3){ref-type="fig"}A). This unfavorable prognostic effect occurred in MSS/MSI-L (*p* = 0.0532) and showed a trend in MSI-H (*p* = 0.2515; Figures [3](#F3){ref-type="fig"}B,C). In contrast, no difference in survival time was noted for patients with *MGMT* methylated or unmethylated tumors (*p* = 0.4966; Figure [3](#F3){ref-type="fig"}D).

![**Kaplan--Meier survival curves showing survival time differences for patients with CIMP-H, CIMP-L, and -negative tumors (A) in the whole patient cohort, (B) in microsatellite stable or instable-low (MSS/MSI-L) and (C) in microsatellite instable-high (MSI-H) cases, and (D) for patients stratified by *MGMT* status**.](fonc-02-00007-g003){#F3}

Classification and regression tree analysis
-------------------------------------------

Of the 304 fully molecularly characterized patients, 302 had survival time information and were entered CART analysis. This approach was used to classify patients into prognostic groups using 10 year survival as the clinical endpoint (Figure [4](#F4){ref-type="fig"}A). *BRAF* gene mutation was identified as the most important parameter and classified as a single group. Patients with *BRAF* WT tumors were further discriminated based on CIMP status; patients with any methylation of CpG islands (CIMP-H and CIMP-L) formed a separate prognostic group. CIMP-negative patients were further subdivided by *KRAS* gene status. The remaining classification by MSI or *MGMT* methylation yielded little additional discrimination. The frequency of these subgroups is shown in Figure [4](#F4){ref-type="fig"}B. Ten year survival for the most important subgroups underline a rate of 10% (95% CI: 1--32; *n* = 30) for patients with *BRAF* mutated tumors, followed by 38% (95%CI: 29--47; *n* = 118) for *BRAF* WT, CIMP-H, or CIMP-L tumors, then 50% (95%CI: 32--62; *n* = 112) for *BRAF* WT, CIMP-negative, *KRAS* WT cases, and 55% (95%CI: 23--72; *n* = 42) for *BRAF* WT, CIMP-negative, *KRAS* mutated cases. Hence, three major groups of patients were identified: *BRAF* mutated, CIMP-H or CIMP-L, and CIMP-negative (*p* = 0.034).

![**(A)** Analysis of the five molecular features using classification and regression tree analysis shows the hierarchy of most discriminating alterations and prognostic subgroups, namely subgroup 1: *BRAF* mutation, subgroup 2: CIMP-high, and CIMP-low and subgroup 3: CIMP-negative. *KRAS*, *MGMT*, and MSI contribute only little additional prognostic information. **(B)** Frequencies of each new subgroup.](fonc-02-00007-g004){#F4}

Discussion
==========

Our results suggest that Jass's model of colorectal cancer cannot effectively classify patients from the institutes included in this study into molecular subgroups. Here, we analyze the reasons for this discordance.

We used pyrosequencing rather than MethyLight or methylation-specific PCR (MSP) to quantify methylation at CpG islands. This is a novel yet validated method for investigating CpG site methylation from paraffin-embedded tissues (Colella et al., [@B4]; Tost et al., [@B23]; Potapova et al., [@B19]). In contrast to MethyLight and MSP, each CpG site is assigned a percentage of methylation. This has several advantages; among others, it allows us to take into consideration the background methylation of the adjacent non-neoplastic tissue and assign a tumor-specific methylation score by subtracting out this signal. This is particularly interesting in the case of CDKN2A where age-related methylation can occur more frequently (Toyota et al., [@B24]).

In this study we evaluated the following five CIMP genes: *CACNA1G*, *NEUROG1*, *CDKN2A*, *CRABP1*, and *MLH1*. Not only has this same panel been used in previous studies (Ogino et al., [@B16]), but a comparison study of the performance characteristics of these genes has shown them to be reliable for the detection of CIMP phenotype (Ogino et al., [@B17]). Although we used a stringent criterion for determining methylation-positivity of each gene (minimal 30% difference between tumor and non-neoplastic CpG methylation), we nonetheless obtain rates comparable to those published by others. Our frequency of 16% for CDKN2A is slightly lower than that of Ogino and Nosho using MethyLight assays (29, 30%) but similar to Ahn et al. ([@B1]) and also Yu et al. ([@B28]) using pyrosequencing (16 and 20%, respectively; Ogino et al., [@B17]; Nosho et al., [@B15]). Our finding of methylation in 33% *MGMT*, 22% for *NEUROG1*, and 14% for *CACNA1G* is similar to the 38, 32, and 13% reported by Nosho and Lee while the 17% obtained for *MLH1* is also within the expected range documented by others (6--28%; Ogino et al., [@B17]; Lee et al., [@B14]; Nosho et al., [@B15]; Ahn et al., [@B1]).

We defined CIMP-H and CIMP-L as at least four/five and one to three methylated genes, respectively. Dahlin et al. ([@B6]) characterized CIMP-L and CIMP-H as hypermethylation in one to five and six to eight genes using the MethyLight method. Jover et al. ([@B10]) considered CIMP+ as aberrant methylation in at least three/five genes (25% CIMP+ rate). Kim et al. ([@B11]), also using pyrosequencing show a CIMP+ rate of 35.8% when considering hypermethylation of at least two/seven genes while Van Rijnsoever et al. ([@B26]) report a 32% CIMP +  rate referring to at least two/three methylated sites. Finally, Ogino et al. ([@B18]) used an eight-marker panel and defined CIMP-H as at least six/eight methylated promoters by MethyLight assays. There is to date no consensus regarding the number of methylated genes to be included in the definition of CIMP.

Our frequency of CIMP-H and -L is 7.1 and 43%, respectively. Dahlin et al. ([@B6]) evaluated three prospective European population-based cohorts (together termed the Northern Sweden Health and Disease Study, NSHDS) followed by a second expanded series (Colorectal cancer in Umeo Study, CRUMS) including 190 and 414 patients. Stratifying by MSS status, they report a 7.4 and 6.8% CIMP-H rate in the MSS and MSI tumors of the NSHDS and 3.0 and 8.8% CIMP-H rate for MSS and MSI tumors, respectively in the larger CRUMS. Therefore, although the frequency of CIMP-H in this study is lower than expected, it is in accordance with these larger European studies. More importantly, the poor prognostic effect observed here in patients with CIMP-H and CIMP-L tumors in comparison to those showing CIMP-negativity agrees with several works from other authors (Ward et al., [@B27]; Kim et al., [@B12]; Dahlin et al., [@B6]). In addition, our findings show no association of *MGMT* methylation with prognosis, a result which was also recently observed by Shima et al. ([@B22]).

A recent review by Curtin et al. ([@B5]), stresses that in contrast to the relatively straightforward determination of MSI tumor status, a consensus panel of CpG sites for CIMP determination has not yet been made. To date, studies evaluating CIMP have shown considerable variability in the selection of CIMP-related promoters, definition of threshold values, and variation in the number of methylated genes to define CIMP-L and CIMP-H. In this study 41% of all cases could not be classified into any one of Jass's five proposed molecular subgroups. Eighty-six percent of these unclassifiable cases were CIMP-L and 11% CIMP-H. This finding stresses again that the definition of CIMP status can significantly compromise the validation of a molecular classification of colorectal cancer based on three categories of CIMP. One possibility would be to evaluate CIMP-negative versus CIMP+ tumor, regardless of the degree of methylation. Supporting this further, our study here shows that in the case of *BRAF* wild-type patients, CIMP-L, and H cancers segregate together in CART analysis.

Although evidence suggests that CIMP not only plays a major role in the pathogenesis but also in the prognosis of patients with colorectal cancer, an effective classification is clearly hindered by the definition of high and low-level CIMP. The selection of promoter regions, number of CpG sites, analysis method and cut-off values leading to standardized definitions of CIMP status all warrant considerable investigation.
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